Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Brain metastases in HER2-positive breast cancer: current and novel treatment strategies. Cancers (Basel). 2021;13:2927.
Article CAS PubMed Google Scholar
Zimmer AS, Van Swearingen AED, Anders CK. HER2-positive breast cancer brain metastasis: a new and exciting landscape. Cancer Rep (Hoboken). 2020;5: e1274.
Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, et al. Brain metastases in newly diagnosed breast cancer: a population-based study. JAMA Oncol. 2017;3:1069–77.
Article PubMed PubMed Central Google Scholar
Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1–01). Lancet Oncol. 2013;14:244–8.
Article CAS PubMed Google Scholar
Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ, Steeg PS. CNS metastases in breast cancer: old challenge, new frontiers. Clin Cancer Res. 2013;19:6404–18.
Article CAS PubMed PubMed Central Google Scholar
Wang J, Xu B. Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduct Target Ther. 2019;4:34.
Article PubMed PubMed Central Google Scholar
Elias SG, Adams A, Wisner DJ, Esserman LJ, van T Veer LJ, et al. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23:1464–83.
Article CAS PubMed Google Scholar
Marchiò C, Annaratone L, Marques A, Casorzo L, Berrino E, Sapino A. Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. Semin Cancer Biol. 2021;72:123–5.
Giordano SH, Temin S, Chandarlapaty S, Crews JR, Esteva FJ, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36:2736–40.
Cortés J, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143–54.
Yeh R-H, Yu J-C, Chu C-H, Ho C-L, Kao H-W, Liao G-S, et al. Distinct MR imaging features of triple-negative breast cancer with brain metastasis. J Neuroimaging. 2015;25:474–81.
Hadjipanteli A, Doolan P, Kyriacou E, Constantinidou A. Breast cancer brain metastasis: the potential role of MRI beyond current clinical applications. Cancer Manag Res. 2020;12:9953–64.
Article CAS PubMed PubMed Central Google Scholar
Hoefnagel LDC, van de Vijver MJ, van Slooten H-J, Wesseling P, Wesseling J, Westenend PJ, et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 2010;12:R75–R75.
Article PubMed PubMed Central Google Scholar
Hulsbergen AFC, Claes A, Kavouridis VK, Ansaripour A, Nogarede C, Hughes ME, et al. Subtype switching in breast cancer brain metastases: a multicenter analysis. Neuro Oncol. 2020;22:1173–81.
Article CAS PubMed PubMed Central Google Scholar
Thomson AH, McGrane J, Mathew J, Palmer J, Hilton DA, Purvis G, et al. Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes. Br J Cancer. 2016;114:793–800.
Article CAS PubMed PubMed Central Google Scholar
Chang S, Chesney J, Trent JO, Telang S. Abstract 2519: Targeting glucose metabolism in HER2+breast cancer. Cancer Res. 2021;81:2519–619.
Farhadi P, Yarani R, Valipour E, Kiani S, Hoseinkhani Z, Mansouri K. Cell line-directed breast cancer research based on glucose metabolism status. Biomed Pharmacother. 2022;146: 112526.
Article CAS PubMed Google Scholar
Kim JY, Lee SH, Kim S, Kang T, Bae YT. Tumour 18 F-FDG uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol. 2015;25:1172–81.
Nitchingham A, Pereira JV, Wegner EA, Oxenham V, Close J, Caplan GA. Regional cerebral hypometabolism on 18F-FDG PET/CT scan in delirium is independent of acute illness and dementia. Alzheimers Dement. 2023;19:97–106.
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018;142:1364–82.
Swain SM, Miles D, Kim S-B, Im Y-H, Im S-A, Semiglazov V, et al. End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). J Clin Oncol. 2019;37:1020–120.
Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2019;382:610–21.
Article PubMed PubMed Central Google Scholar
Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA Trial. J Clin Oncol. 2020;38:3138–49.
Article CAS PubMed PubMed Central Google Scholar
Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38:2610–9.
Article CAS PubMed PubMed Central Google Scholar
Linzer RW, Guida DL, Aminov J, Snider JM, Khalife G, Buyukbayraktar AB, et al. Dihydroceramide desaturase 1 (DES1) promotes anchorage-independent survival downstream of HER2-driven glucose uptake and metabolism. FASEB J. 2022;36: e22558.
Article CAS PubMed Google Scholar
Kyeong S, Cha YJ, Ahn SG, Suh SH, Son EJ, Ahn SJ. Subtypes of breast cancer show different spatial distributions of brain metastases. PLoS ONE. 2017;12: e0188542.
Article PubMed PubMed Central Google Scholar
Laakmann E, Witzel I, Scriba V, Grzyska U, Zu Eulenburg C, Burchardi N, et al. Radiological patterns of brain metastases in breast cancer patients: a subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry. Int J Mol Sci. 2016;17:1615.
Article PubMed PubMed Central Google Scholar
Ahn SJ, Park M, Bang S, Cho E, Ahn SG, Suh SH, et al. Apparent diffusion coefficient histogram in breast cancer brain metastases may predict their biological subtype and progression. Sci Rep. 2018;8:9947.
Article PubMed PubMed Central Google Scholar
Ulu E, Ozturk B, Atalay K, Okumus IB, Erdem D, Gul MK, et al. Diffusion-weighted imaging of brain metastasis: correlation of MRI parameters with histologic type. Turk Neurosurg. 2022;32:58–68.
Young JR, Ressler JA, Mortimer JE, Schmolze D, Fitzgibbons M, Chen BT. Performance of enhancement on brain MRI for identifying HER2 overexpression in breast cancer brain metastases. Eur J Radiol. 2021;144: 109948.
Young JR, Ressler JA, Mortimer JE, Schmolze D, Fitzgibbons M, Chen BT. Association of lesion contour and lesion composition on MR with HER2 status in breast cancer brain metastases. Magn Reson Imaging. 2023;96:60–6.
Article CAS PubMed Google Scholar
Young JR, Ressler JA, Shiroishi MS, Mortimer JE, Schmolze D, Fitzgibbons M, et al. Association of relative cerebral blood volume from dynamic susceptibility contrast-enhanced perfusion MR with HER2 status in breast cancer brain metastases. Acad Radiol. 2023;30:1816–22.
Comments (0)